Compare Moderna, Inc. (MRNA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs New York Times Co — how do they compare? Moderna, Inc. trades at $136.84 (market cap $54.14B), while New York Times Co trades at $66.6 (market cap $10.74B). The key difference: Moderna, Inc. is far larger — about 5× New York Times Co's market cap, and New York Times Co pays a 1.38% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NYT | |
|---|---|---|
Market Cap | $54.14B | $10.74B |
Sector | Health | Media |
52-Week High | $174.38 | $85.86 |
52-Week Low | $22.36 | $54.66 |
Enterprise Value | $50.29B | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight strong operational performance, supported by rising revenue and net income margins. The stock's valuation metrics include a P/E of 28.32 and P/S of 3.75, while positive cash flow trends and a dividend payment reflect financial stability.
Outlook remains cautiously optimistic with a consensus price target of $76.00, offering potential upside. Key risks include ongoing legal challenges with OpenAI over copyright issues and competitive pressures in digital media. Institutional interest is evident, but regulatory and market sentiment uncertainties warrant monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
